title: [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
abstract: Anti-CD20 monoclonal antibodies are currently used for non-Hodgkin's lymphoma treatment and Rituximab (MabThera) and ibritumomab-tiuxetan (Zevalin) currently approved for clinical use. Rituximab has improved survival of patients with follicular and diffuse large B cells lymphoma. Rituximab is safe with uncommon side effects mainly observed during the first infusion. It is basically used associated with chemotherapy every three weeks and also as maintenance therapy for relapsed follicular lymphoma. A better understand of its mechanisms of action has allowed to develop new generation of monoclonal antibody currently tested in clinical trials.
authors.affiliation: Service d'hématologie et centre d'Investigation clinique des biothérapies, CHU de Montpellier, 34295 Montpellier.
authors.forename: Franciane
authors.initials: F
authors.lastname: Paul
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Rossi
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cartron
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; C422802:ibritumomab tiuxetan